Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.


CONTEXT In June 2006, the Food and Drug Administration licensed the quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine (qHPV) in the United States for use in females aged 9 to 26 years; the Advisory Committee on Immunization Practices then recommended qHPV for routine vaccination of girls aged 11 to 12 years. OBJECTIVE To… (More)
DOI: 10.1001/jama.2009.1201


2 Figures and Tables

Blog articles referencing this paper

Slides referencing similar topics